Medicamen Biotech (NSE:MEDICAMEQ) Moat Score: 0/10 (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MEDICAMEQ Medicamen Biotech Ltd NSE:MEDICAMEQ
69 GF Score
Price ₹248.88
GF Value ₹487.84
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Medicamen Biotech Moat Score?

Medicamen Biotech has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Medicamen Biotech has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medicamen Biotech might have No Moat - No discernible moat.

Medicamen Biotech  (NSE:MEDICAMEQ) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medicamen Biotech Moat Score Related Terms

NSE:MEDICAMEQ
69GF Score
Medicamen Biotech Ltd NSE:MEDICAMEQ
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medicamen Biotech (NSE:MEDICAMEQ) Overvalued in 2026?

Based on GuruFocus' analysis, Medicamen Biotech stock appears to be undervalued. The current stock price of ₹248.88 is trading 49% below its estimated GF Value™ of ₹487.84. GuruFocus considers Medicamen Biotech to be Possible Value Trap.

Key valuation signals for NSE:MEDICAMEQ:

  • Moat Score: 0
  • GF Value™: ₹487.84 vs. price of ₹248.88 (49% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the NSE:MEDICAMEQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicamen Biotech Business Description

Other Exchanges 531146:India
Address 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, IND, 110019
Medicamen Biotech Ltd is an Indian based pharmaceutical company. The company is engaged in developing and manufacturing Pharmaceuticals formulations products. It manufactures Tablets, Capsules, Oral liquids, Dry syrups, Ointments, and Oral rehydration solution. It generates revenue from the sale of pharmaceutical products.
69GF Score

Get the complete analysis for NSE:MEDICAMEQ

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹248.88
Price
₹487.84
GF Value